Skip to contentB
Bio-Rad Laboratories, Inc.
B
BIOBio-Rad Laboratories, Inc. Q4 2013 · 10-K
Revenue$602.60M$602.60M+5.0% vs Q4 2012 Net Income$30.10M$30.10M−28.3% vs Q4 2012 EPS Diluted$1.04$1.04−28.8% vs Q4 2012 Gross Profit$322,700,000+2.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bio-Rad Laboratories, Inc. · CIK 12208 · Engraved from SEC EDGAR
derived
Operating Cash Flowderived$70,550,000−18.2% Free Cash Flowderived$42,830,000−23.2% Margins · derivedGross margin53.6%−1.2 pt vs Q4 2012
Operating margin8.7%−3.6 pt vs Q4 2012
Net margin5.0%−2.3 pt vs Q4 2012
ended Dec 31, 2013 · filed Mar 18, 2014 · 77 d after period end